Report cover image

Global GLP-1 Drug Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 197 Pages
SKU # APRC20280286

Description

Summary

According to APO Research, the global GLP-1 Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for GLP-1 Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for GLP-1 Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the GLP-1 Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for GLP-1 Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the GLP-1 Drug market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline (GSK), Hanmi Pharmaceutical Co, Novo Nordisk, Pfizer Inc, Sanofi and Teva Pharmaceutical Industries Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for GLP-1 Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of GLP-1 Drug, also provides the sales of main regions and countries. Of the upcoming market potential for GLP-1 Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the GLP-1 Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global GLP-1 Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for GLP-1 Drug sales, projected growth trends, production technology, application and end-user industry.

GLP-1 Drug Segment by Company

AstraZeneca
Boehringer Ingelheim
Eli Lilly
GlaxoSmithKline (GSK)
Hanmi Pharmaceutical Co
Novo Nordisk
Pfizer Inc
Sanofi
Teva Pharmaceutical Industries Ltd
Gan & Lee Pharmaceuticals
Huadong Medicine
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
PegBio Co., Ltd
Shanghai Benemae Pharmaceutical Corporation
Tonghua Dongbao
GLP-1 Drug Segment by Type

Short-acting GLP-1 Drug
Long-acting GLP-1 Drug
GLP-1 Drug Segment by Application

Type 2 Diabetes (T2DM)
Alzheimer's Disease (AD)
Non-alcoholic Steatohepatitis (NASH)
Obesity
Cardiovascular and Cerebrovascular Diseases (CVD)
GLP-1 Drug Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global GLP-1 Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions GLP-1 Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify GLP-1 Drug significant trends, drivers, influence factors in global and regions.
6. To analyze GLP-1 Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Drug industry.
Chapter 3: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of GLP-1 Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of GLP-1 Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global GLP-1 Drug Sales Value (2020-2031)
1.2.2 Global GLP-1 Drug Sales Volume (2020-2031)
1.2.3 Global GLP-1 Drug Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 GLP-1 Drug Market Dynamics
2.1 GLP-1 Drug Industry Trends
2.2 GLP-1 Drug Industry Drivers
2.3 GLP-1 Drug Industry Opportunities and Challenges
2.4 GLP-1 Drug Industry Restraints
3 GLP-1 Drug Market by Company
3.1 Global GLP-1 Drug Company Revenue Ranking in 2024
3.2 Global GLP-1 Drug Revenue by Company (2020-2025)
3.3 Global GLP-1 Drug Sales Volume by Company (2020-2025)
3.4 Global GLP-1 Drug Average Price by Company (2020-2025)
3.5 Global GLP-1 Drug Company Ranking (2023-2025)
3.6 Global GLP-1 Drug Company Manufacturing Base and Headquarters
3.7 Global GLP-1 Drug Company Product Type and Application
3.8 Global GLP-1 Drug Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global GLP-1 Drug Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 GLP-1 Drug Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 GLP-1 Drug Market by Type
4.1 GLP-1 Drug Type Introduction
4.1.1 Short-acting GLP-1 Drug
4.1.2 Long-acting GLP-1 Drug
4.2 Global GLP-1 Drug Sales Volume by Type
4.2.1 Global GLP-1 Drug Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global GLP-1 Drug Sales Volume by Type (2020-2031)
4.2.3 Global GLP-1 Drug Sales Volume Share by Type (2020-2031)
4.3 Global GLP-1 Drug Sales Value by Type
4.3.1 Global GLP-1 Drug Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global GLP-1 Drug Sales Value by Type (2020-2031)
4.3.3 Global GLP-1 Drug Sales Value Share by Type (2020-2031)
5 GLP-1 Drug Market by Application
5.1 GLP-1 Drug Application Introduction
5.1.1 Type 2 Diabetes (T2DM)
5.1.2 Alzheimer's Disease (AD)
5.1.3 Non-alcoholic Steatohepatitis (NASH)
5.1.4 Obesity
5.1.5 Cardiovascular and Cerebrovascular Diseases (CVD)
5.2 Global GLP-1 Drug Sales Volume by Application
5.2.1 Global GLP-1 Drug Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global GLP-1 Drug Sales Volume by Application (2020-2031)
5.2.3 Global GLP-1 Drug Sales Volume Share by Application (2020-2031)
5.3 Global GLP-1 Drug Sales Value by Application
5.3.1 Global GLP-1 Drug Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global GLP-1 Drug Sales Value by Application (2020-2031)
5.3.3 Global GLP-1 Drug Sales Value Share by Application (2020-2031)
6 GLP-1 Drug Regional Sales and Value Analysis
6.1 Global GLP-1 Drug Sales by Region: 2020 VS 2024 VS 2031
6.2 Global GLP-1 Drug Sales by Region (2020-2031)
6.2.1 Global GLP-1 Drug Sales by Region: 2020-2025
6.2.2 Global GLP-1 Drug Sales by Region (2026-2031)
6.3 Global GLP-1 Drug Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global GLP-1 Drug Sales Value by Region (2020-2031)
6.4.1 Global GLP-1 Drug Sales Value by Region: 2020-2025
6.4.2 Global GLP-1 Drug Sales Value by Region (2026-2031)
6.5 Global GLP-1 Drug Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America GLP-1 Drug Sales Value (2020-2031)
6.6.2 North America GLP-1 Drug Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe GLP-1 Drug Sales Value (2020-2031)
6.7.2 Europe GLP-1 Drug Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific GLP-1 Drug Sales Value (2020-2031)
6.8.2 Asia-Pacific GLP-1 Drug Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America GLP-1 Drug Sales Value (2020-2031)
6.9.2 South America GLP-1 Drug Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa GLP-1 Drug Sales Value (2020-2031)
6.10.2 Middle East & Africa GLP-1 Drug Sales Value Share by Country, 2024 VS 2031
7 GLP-1 Drug Country-level Sales and Value Analysis
7.1 Global GLP-1 Drug Sales by Country: 2020 VS 2024 VS 2031
7.2 Global GLP-1 Drug Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global GLP-1 Drug Sales by Country (2020-2031)
7.3.1 Global GLP-1 Drug Sales by Country (2020-2025)
7.3.2 Global GLP-1 Drug Sales by Country (2026-2031)
7.4 Global GLP-1 Drug Sales Value by Country (2020-2031)
7.4.1 Global GLP-1 Drug Sales Value by Country (2020-2025)
7.4.2 Global GLP-1 Drug Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.5.2 USA GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.5.3 USA GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.6.2 Canada GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.6.2 Mexico GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.8.2 Germany GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.9.2 France GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.9.3 France GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.10.2 U.K. GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.11.2 Italy GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.12.2 Spain GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.13.2 Russia GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.16.2 China GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.16.3 China GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.17.2 Japan GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.18.2 South Korea GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.19.2 India GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.19.3 India GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.20.2 Australia GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.22.2 Brazil GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.23.2 Argentina GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.24.2 Chile GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.25.2 Colombia GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.26.2 Peru GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.28.2 Israel GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.29.2 UAE GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.30.2 Turkey GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.31.2 Iran GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt GLP-1 Drug Sales Value Growth Rate (2020-2031)
7.32.2 Egypt GLP-1 Drug Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt GLP-1 Drug Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 AstraZeneca
8.1.1 AstraZeneca Comapny Information
8.1.2 AstraZeneca Business Overview
8.1.3 AstraZeneca GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.1.4 AstraZeneca GLP-1 Drug Product Portfolio
8.1.5 AstraZeneca Recent Developments
8.2 Boehringer Ingelheim
8.2.1 Boehringer Ingelheim Comapny Information
8.2.2 Boehringer Ingelheim Business Overview
8.2.3 Boehringer Ingelheim GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.2.4 Boehringer Ingelheim GLP-1 Drug Product Portfolio
8.2.5 Boehringer Ingelheim Recent Developments
8.3 Eli Lilly
8.3.1 Eli Lilly Comapny Information
8.3.2 Eli Lilly Business Overview
8.3.3 Eli Lilly GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.3.4 Eli Lilly GLP-1 Drug Product Portfolio
8.3.5 Eli Lilly Recent Developments
8.4 GlaxoSmithKline (GSK)
8.4.1 GlaxoSmithKline (GSK) Comapny Information
8.4.2 GlaxoSmithKline (GSK) Business Overview
8.4.3 GlaxoSmithKline (GSK) GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.4.4 GlaxoSmithKline (GSK) GLP-1 Drug Product Portfolio
8.4.5 GlaxoSmithKline (GSK) Recent Developments
8.5 Hanmi Pharmaceutical Co
8.5.1 Hanmi Pharmaceutical Co Comapny Information
8.5.2 Hanmi Pharmaceutical Co Business Overview
8.5.3 Hanmi Pharmaceutical Co GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.5.4 Hanmi Pharmaceutical Co GLP-1 Drug Product Portfolio
8.5.5 Hanmi Pharmaceutical Co Recent Developments
8.6 Novo Nordisk
8.6.1 Novo Nordisk Comapny Information
8.6.2 Novo Nordisk Business Overview
8.6.3 Novo Nordisk GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.6.4 Novo Nordisk GLP-1 Drug Product Portfolio
8.6.5 Novo Nordisk Recent Developments
8.7 Pfizer Inc
8.7.1 Pfizer Inc Comapny Information
8.7.2 Pfizer Inc Business Overview
8.7.3 Pfizer Inc GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.7.4 Pfizer Inc GLP-1 Drug Product Portfolio
8.7.5 Pfizer Inc Recent Developments
8.8 Sanofi
8.8.1 Sanofi Comapny Information
8.8.2 Sanofi Business Overview
8.8.3 Sanofi GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.8.4 Sanofi GLP-1 Drug Product Portfolio
8.8.5 Sanofi Recent Developments
8.9 Teva Pharmaceutical Industries Ltd
8.9.1 Teva Pharmaceutical Industries Ltd Comapny Information
8.9.2 Teva Pharmaceutical Industries Ltd Business Overview
8.9.3 Teva Pharmaceutical Industries Ltd GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.9.4 Teva Pharmaceutical Industries Ltd GLP-1 Drug Product Portfolio
8.9.5 Teva Pharmaceutical Industries Ltd Recent Developments
8.10 Gan & Lee Pharmaceuticals
8.10.1 Gan & Lee Pharmaceuticals Comapny Information
8.10.2 Gan & Lee Pharmaceuticals Business Overview
8.10.3 Gan & Lee Pharmaceuticals GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.10.4 Gan & Lee Pharmaceuticals GLP-1 Drug Product Portfolio
8.10.5 Gan & Lee Pharmaceuticals Recent Developments
8.11 Huadong Medicine
8.11.1 Huadong Medicine Comapny Information
8.11.2 Huadong Medicine Business Overview
8.11.3 Huadong Medicine GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.11.4 Huadong Medicine GLP-1 Drug Product Portfolio
8.11.5 Huadong Medicine Recent Developments
8.12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
8.12.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Comapny Information
8.12.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Business Overview
8.12.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.12.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Product Portfolio
8.12.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments
8.13 PegBio Co., Ltd
8.13.1 PegBio Co., Ltd Comapny Information
8.13.2 PegBio Co., Ltd Business Overview
8.13.3 PegBio Co., Ltd GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.13.4 PegBio Co., Ltd GLP-1 Drug Product Portfolio
8.13.5 PegBio Co., Ltd Recent Developments
8.14 Shanghai Benemae Pharmaceutical Corporation
8.14.1 Shanghai Benemae Pharmaceutical Corporation Comapny Information
8.14.2 Shanghai Benemae Pharmaceutical Corporation Business Overview
8.14.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.14.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Product Portfolio
8.14.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments
8.15 Tonghua Dongbao
8.15.1 Tonghua Dongbao Comapny Information
8.15.2 Tonghua Dongbao Business Overview
8.15.3 Tonghua Dongbao GLP-1 Drug Sales, Value and Gross Margin (2020-2025)
8.15.4 Tonghua Dongbao GLP-1 Drug Product Portfolio
8.15.5 Tonghua Dongbao Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 GLP-1 Drug Value Chain Analysis
9.1.1 GLP-1 Drug Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 GLP-1 Drug Sales Mode & Process
9.2 GLP-1 Drug Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 GLP-1 Drug Distributors
9.2.3 GLP-1 Drug Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.